S
pontaneous coronary artery dissection (SCAD) is a rare nonatherosclerotic cause of acute coronary syndromes with a prevalence rate of 0.07%-1.1%. 1, 2 SCAD was first described in 1931, with many early cases discovered in autopsy series after sudden cardiac death. The view of SCAD as a rare, fatal disorder changed on increased diagnosis with coronary angiography and more recently with the introduction of novel imaging technologies such as optical coherence tomography. 3, 4 Arterial dissection is characterized by a hematoma inside the arterial media or between the media and either the adventitia or intima, creating a false lumen that compresses the true lumen. This compression decreases luminal blood flow and can result in myocardial ischemia and infarction. 5 SCAD typically affects younger women with low rates of known acute coronary syndromes risk factors (average age, 30-45 years; 70% female) and has been found to play a role in as many as 40% of heart attack cases in women under the age of 50 years. 5 SCAD shares characteristics of traditional genetically triggered arterial diseases, occurring in young patients and in those often without traditional cardiovascular risk factors. However, large pedigrees segregating SCAD have not been described. A sizable number of SCAD patients coexpress fibromuscular dysplasia (FMD) and the peripartum state, although these connections do not account for all SCAD cases (45% to 72% and 2.4%, respectively). 6, 7 Individual case reports and retrospective analyses have described SCAD in genetically triggered vascular conditions such as Marfan syndrome (MFS), vascular Ehlers-Danlos syndrome (vEDS), 8, 9 or
Loeys-Dietz syndrome (LDS), [10] [11] [12] and occasional familial cases have been seen. 13 As these disorders are known to show a widespread vascular fragility, it seems reasonable to suspect that they may play a role in coronary artery dissection. 14 Our study sought to explore the contribution of identifiable genetically triggered disorders to SCAD in a tertiary care hospital population. We conducted a prospective study to examine the demographics, genetic information, and physical examination findings of 73 SCAD patients who underwent prospective cardiovascular genetic evaluation at the Massachusetts General Hospital (MGH) between July 2013 and September 2017.
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Study Population
The study was approved by Partners Healthcare Institutional Review Board. The study included 107 patients consented and enrolled in the MGH SCAD registry between July 2013 and September 2017. The registry consisted of patients who presented with SCAD at MGH were referred by another provider or were self-referred. Evaluation in cardiovascular genetics clinic (CGC) was offered to all patients during the time period of the study. Reasons for the discrepancy between the numbers of patients in the study population (107) and those evaluated (73) in CGC were not systemically recorded but included distance from the hospital, lack of interest, and insurancebased provider restrictions. All patient photographs are presented with patient permission and written signed consent.
Clinic Evaluation
Of 107 patients with full clinical data, 73 patients were evaluated in CGC to consider any underlying genetic disorders that may have predisposed to SCAD. All patients were examined by the senior author (Dr Lindsay). Physical features typical of MFS, vEDS, and LDS were investigated and entered into a RedCap database ( Figure I in the Data Supplement). A 4 generation pedigree was obtained for all patients. Family history was also examined and noted for SCAD, aneurysm, and dissection, known connective tissue disorders (CTDs) and associations. For the purpose of family history, early-onset myocardial infarction was defined as age <65 for women and <55 for men. Genetic panels from multiple facilities were used, including Invitae, Ambry, Gene Dx, Prevention Genetics,
CLINICAL PERSPECTIVE
The lack of traditional cardiovascular risk factors of patients with spontaneous coronary artery dissection often prompts clinical consideration of genetically-mediated vascular conditions. In this study, we described the prospective cardiovascular genetics evaluation of patients with spontaneous coronary artery dissection. What are the clinical implications?
• In this series, ≈5% of patients were diagnosed with Mendelian vascular disease.
• Patients with positive molecular genetic testing were younger on average than patients with negative testing.
• Arterial fibromuscular dysplasia was not seen in patients with genetically triggered vascular disease.
• Vascular Ehlers-Danlos syndrome was the most commonly identified Mendelian disorder in this population.
In summary, cardiovascular genetics evaluation seems appropriate for patients with spontaneous coronary artery dissection, especially in the young. 
Statistical Analysis
Categorical variables were presented as frequencies and percentages, and continuous variables were expressed as mean±SD. Categorical variables were analyzed using Fisher exact test, and continuous variables were analyzed using Student t test, where appropriate. Data analysis was performed using Stata/SE 14.1 (College Station, TX: StataCorp LP.). All reported P values were 2-sided, and a value of P<0.05 was considered statistically significant.
Imaging Protocol
A full vascular imaging evaluation (head, neck, chest, and abdomen Computed Tomography Angiogram or Magnetic Resonance Angiogram) was recommended for all patients at the time of presentation to screen for disseminated vascular disease including aneurysm or previous dissection as well as stenotic pathology associated with FMD.
RESULTS

Baseline Characteristics
We examined 107 patients with full clinical data available in our SCAD database. Seventy-three of these patients underwent evaluation in CGC (Figure 1 ). Demographically, these 73 patients appeared similar to the 34 patients who were not evaluated in CGC (Table II in the Data Supplement). Most of the patients evaluated were women (85.3% female with a mean age at first SCAD event of 45.3±9.4 years). The majority of the population did not exhibit common risk factors for acute coronary syndromes, including hypertension, hyperlipidemia, diabetes mellitus, and smoking. FMD was present in 28.8% of the group evaluated in CGC (Table 1) . After a clinic evaluation involving capturing a full family and medical history, physical examination focusing on features of syndromic vascular disease, and review of cardiovascular imaging, molecular genetic testing was discussed with all patients. Eight patients had undergone genetic testing at outside facilities before or concurrent with our initial evaluation. Of these 8 patients, 4 had positive test results and 3 of these were diagnosed with a genetic disorder before their SCAD event. In our clinic, features such as positive family history, suspicious physical examination findings, young age, or systemic vascular involvement prompted a recommendation of genetic testing. However, because of the incomplete genetic understanding of SCAD, testing was occasionally offered to motivated patients. Thirty-six patients who had not previously been tested underwent genetic testing in our clinic ( Figure 1 ). To better understand differences between individuals who underwent genetic testing and those who did not, we chose to compare these 2 groups. In general, the presentation of patients with a SCAD event was similar between these 2 groups, although some differences were noted (Table 1) . Patients who underwent genetic testing were slightly younger (43.6±9.6 versus 48.0±8.5 years; P=0.04) and more likely to be male (female [n]%, [35/44] 79.6% versus [28/29] 96.6%; P=0.04) than those who did not, although both were of marginal significance. Patients with personal history of other dissections, aneurysms, and recurrent SCAD were more likely to be tested, although this difference was not statistically significant (Table 1) . We next chose to investigate possible differences in SCAD presentation. The left anterior descending artery was the most common dissection location in both groups, and both ST-segment-elevation myocardial infarction and non-ST-segment-elevation myocardial infarction were common presentations. (Table 2 ). Physical activity levels of patients before their SCAD event was nearly identical between groups.
Physical Characteristics and Family History
Out of the 73 patients evaluated, 79.4% exhibited one or more physical features characteristic of a heritable CTDs, although none had a systemic MFS score of >4. 15 Among those with identifiable features, the most common were myopia and translucent skin (25.8% and 16.1%, respectively). There were no significant differences in CTD physical findings between FMD and non-FMD patients (all P>0.05; Table III in the Data Supplement).
In general, SCAD patients did not have a strong family history of SCAD or other vascular disease. Only 1 patient had a family history of SCAD (a first cousin with a SCAD event; Figure 2 ). Furthermore, patients did not have a strong family history of CTDs, aneurysms, or dissections as only 3 patients had a first-degree relative with a CTD, 12 had first-and second-degree relative with an aneu-rysm and only 1 patient had a second-degree relative with a dissection (Figure 2 ; Table 3 ). Although as both aneurysms and dissections may be asymptomatic, the true prevalence in these relatives may be higher. D1 indicates first diagonal artery; D2, second diagonal artery; D3, third diagonal artery; LAD, left anterior descending artery; LCx, left circumflex artery; NSTEMI, non-ST-segment-elevation myocardial infarction; OM, obtuse marginal artery; PDA, posterior descending artery; RCA, right coronary artery; S1, first septal artery; S2, second septal artery; SCAD, spontaneous coronary artery dissection; and STEMI, ST-segment-elevation myocardial infarction. Figure 1 ). In all, 40.9% had a finding reported as either a VUS (Table 4; Table I in the Data Supplement) or pathogenic. Six of the 44 patients (13.6%) who received genetic testing overall were diagnosed with a genetic disorder mediating susceptibility (Table 5; Figure 3 ). Three patients had pathological mutations in COL3A1, the causative gene in vEDS, whereas 1 patient was found to exhibit autosomal dominant polycystic kidney disease with a mutation in PKD1, 1 with LDS and a mutation in SMAD3, and 1 with Nail-patella syndrome and mutation in LMX1B (Table 5 ). An additional 12 patients had VUS in one of the tested genes (Table 4) . Comparative demographics between patients with positive and negative gene testing were similar, with the exception of a younger age at first SCAD in those who tested positive (34.5±8.0 versus 45.0±9.0; P=0.02; Table 6 ).
Genetic Testing
Individual Pathogenic Mutations
SCAD has been reported in patients with genetically triggered vascular disorders, including MFS, vEDS, and LDS. 11, [16] [17] [18] Overall, the study population had a low rate of physical examination findings consistent with MFS (Table III in the Data Supplement), and no patients had either a pathogenic mutation or VUS in the FBN1 gene. Three patients had pathological mutations in COL3A1, the causative gene in vEDS, resulting in a rate of 4.1% in the overall evaluated SCAD population. vEDS has been reported in several SCAD studies. 11, 12 One patient was diagnosed and tested after a nontraumatic retroperitoneal hematoma at age 35 (SCAD_89) who had a single SCAD event at age 38. Two others had the diagnosis suspected after their SCAD event (SCAD_3 and 118). Patient SCAD_3 had 2 SCAD events (ages 30 and 34), whereas SCAD_118 is a woman with a single SCAD event at age 21. Two mutations were classic glycine substitutions, whereas 1 was a single base deletion causing a frameshift 19 (Table 4) . Only the patient (SCAD_3) with 2 SCAD events displayed multiple physi- cal features typical of a CTD, including translucent skin, easy bruising, early varicose veins, however, lacking a characteristic facial appearance (Figure 3) .
One woman (SCAD_2) had a previous diagnosis of Nail-patella syndrome and a single SCAD event at age 35. A Thoracic Aortic Aneurysm panel for typical genetically triggered vascular disease was negative. Although SCAD has not previously been described in Nail-patella syndrome, renal artery dissection has been reported. 20 The transcription factor encoded at the LMX1B locus has been implicated in regulatory control of collagens in kidney development, 21 perhaps providing a link between LMX1B and collagen deficiency exhibited in disorders such as vEDS.
One woman (SCAD_132) with the known diagnosis of LDS had a single SCAD event at age 45. Her diagnosis was made after her son suffered a fatal ruptured cerebral aneurysm at age 20. Whole exome sequencing of a differently affected son at an outside facility elucidated a variant in SMAD3 (Table 4) which was subsequently segregated in the family. Her aortic root dimension was 3.9 cm which calculated to a Z score of 2.2, 22 which represents very mild aortic root dilation. She had hindfoot deformity, translucent skin, and a characteristic facial appearance ( Figure 3 ). She had no previous vascular history before her SCAD event.
One patient had a diagnosis of autosomal dominant polycystic kidney disease diagnosed after a vertebral dissection at age 34 and had a single SCAD event at age 38. SCAD has been repeatedly reported in patients with autosomal dominant polycystic kidney disease. [23] [24] [25] [26] [27] [28] [29] She was screened with a Thoracic Aortic Aneurysm panel for typical genetically triggered vascular disease which was negative, whereas PKD1 testing showed 2 novel variants, 1 in a highly conserved residue. These 2 variants are located at the 5′ end of the gene as is typical for PKD1 mutations causing vascular complications. 30 An additional 11 patients had VUS in one of the tested genes (Table 4; Table I in the Data Supplement). One woman (SCAD_96) had 2 pathological variants in the CBS gene indicating a possible diagnosis of homocysteinemia. However, there was normal mental capacity, no abnormalities of skeletal development, ocular disease, or thrombosis and no family history of homocysteinemia. A serum homocysteine level was normal at 7.4 μmol/L. We concluded she was unaffected and she declined further familial segregation of the CBS variants. Another patient (SCAD_10) had a variant in COL3A1 causing a V976A substitution. Interestingly, this variant (c.2927T>A) is absent in Gnomad but has been reported in 2 patients deposited in ClinVar (Accession: SCV000319259.1 and SCV000541801.1) with compatible disease indicating the possibility that this variant is disease-causing, despite a relative lack of sequence conservation and current annotation as a VUS.
DISCUSSION
Cardiovascular genetics evaluation for arterial dissections such as SCAD in young individuals is common, although specific information about the results of such evaluations in the modern era is rare. In this prospective case series, we report the clinical findings and genetic testing of 73 SCAD patients evaluated at the MGH CGC over the last 4 years. The medical features of patients sent for cardiovascular genetic evaluation were similar to those of other case series.
2,31 Consistent with prior observations, SCAD predominantly affects females who often present with myocardial infarction and dissections of the left anterior descending coronary artery (Tables 1 and 2 ). Overall, patients had a very low rate of contributory family history or previous arterial dissections. Physical examination features diagnostic of CTDs were uncommon and were not enriched in patients with FMD. Patients who underwent molecular genetic testing were slightly younger than those who were not, likely reflecting increased suspicion for genetically-mediated disease in younger patients. Among those who underwent testing, patients with pathogenic mutations were younger at the time of their first SCAD event on average than those who tested negative.
Several large studies have been published describing individual institutional series of SCAD patients. The prevalence of identifiable genetic disorders observed in the series by Saw et al 32 was 5%, similar to the 5% noted in the series by Henkin et al. 11 Both of these estimates agree well with the findings in this study. In our total study population, 8.2% of patients had a Mendelian condition. Because patients with rare disease may be more likely to seek care at a tertiary care hospital, we also analyzed patients seen in our clinic who had not previously been diagnosed with a genetic disorder. Among the 36 patients tested at MGH after their SCAD event presenting without previous genetic diagnosis, 2 (5.5%) had positive genetic testing (Figure 1 ). The prevalence of identifiable Mendelian disorders in SCAD in our experience is therefore comparable to other, better described arterial dissec- tion disorders. For instance, the incidence of MFS in the international registry of aortic dissection is ≈5%. 33, 34 SCAD events are known to be associated with the peripartum state, 2,32,35 a feature shared by other forms of arterial dissection including cervical and aortic dissection. [36] [37] [38] In the case of aortic dissection, individuals with CTDs are at particular risk during pregnancy, although those without these disorders also show an elevated risk. 38 We did not note an enrichment in peripartum associated SCAD in patients with genetic disease in this study, although the low numbers in this study likely would not permit observation of such an association if it existed.
In the absence of single-gene, Mendelian disorders, FMD is a common association with SCAD with rates ranging from 45% to 72%. 6, 11, 32, 35 The overall rate in the patients evaluated in our clinic (21/72, 28.8%) is lower than those previously reported. As the modern diagnosis of FMD is based on imaging and as there are not universally utilized guidelines to make this diagnosis, variability in local diagnostic criteria may be responsible for the observed variability in disease prevalence between our series and previous publications. Mendelian disorders have been found to be absent in FMD series, 39, 40 which is similar to our experience. The lack of single gene disorders in FMD implicate a novel genetic architecture. A common variant in the gene PHACTR1 has been associated with FMD, 41 although the causal effect of the variant may be related to endothelin-1 expression rather than PHACTR1 expression.
42 PHACTR1 is not the FMD gene, as familial segregation has not been demonstrated for genes linked to this locus, 41, 42 in fact, the locus has been linked to numerous other vascular disorders. In addition to FMD, this variant has been implicated in diverse vascular disorders such as cervical artery dissection, migraine, and myocardial infarction. [43] [44] [45] What then is the pathogenetic relationship between SCAD and FMD? As demonstrated in this study, the large majority of SCAD cases are individuals without strong family history of vascular disease and with negative genetic testing for monogenic disease. The lack of large pedigrees segregating an independent SCAD phenotype suggest a complex polygenic mode of inheritance for SCAD genetic risk, similar to FMD. In fact, considering the demographic overlap (young age, female predominance) between FMD patients, FMD patients with SCAD, and non-FMD SCAD patients it seems likely that these diseases represent distinct phenotypic manifestations of the same underlying disease entity. Large-scale genotyping of SCAD patients will ultimately be required to dissect this complex genetic predisposition.
COL3A1 Mutations
Pathogenic variants in COL3A1 were the most common positive genetic test finding in our series. COL3A1 mutations impose a risk of generalized tissue fragility, including a risk of vascular dissection in medium and large arteries. Similar to the observed pathology of SCAD events, arterial dissection without preceding aneurysm formation is characteristic of vEDS. In the largest series of patients with vEDS, 737 vascular incidents were reviewed. 8 Of these events, 26/737 (3.5%) represented coronary artery dissections with an average age at the time of SCAD of 30.8±7.8 years old, similar to patients in this study who had positive genetic testing 34.5±8.0 years (Table 6 ). Fourteen patients had anatomic delineation of their SCAD events with approximate equal distribution between the left and right coronary arterial systems. 8 These data indicate genetic testing sent for SCAD should always include analysis of COL3A1.
Implications for Genetic Testing
The frequency of genetic conditions detected in this population (8.2%) suggest a significant number of SCAD patients may have an identifiable genetically triggered vascular disease. FMD vascular pathology seems to be a marker for a lack of association with currently known Mendelian disorders. Therefore, we are currently offering genetic testing to any individual presenting with SCAD without a definitive diagnosis of FMD. Positive family history and physical examination or imaging characteristics typical of Mendelian vascular disease (ie, ascending aortic aneurysm) would clearly lead to a stronger recommendation. We also recommend testing patients with FMD who have more aggressive disease or early-onset presentations, in case of overlapping etiologies, although we have not observed this. In our experience, the female predominance of cases often during reproductive years tends to influence patients toward choosing to undergo genetic testing.
Limitations
Referral bias is inherent because MGH is a tertiary care hospital, and our study population may not represent the true SCAD population. In addition, even though genetic testing was discussed with all 73 patients seen at the CGC, not all accepted. For those who did opt for testing, there was variability in the genes tested for 
